April 22, 2026
2 min watch
In this video, Ursula A. Matulonis, MD, discusses a study assessing letrozole alone compared with standard chemotherapy followed by letrozole maintenance in patients with low-grade serous ovarian, fallopian tube or peritoneal carcinoma.
In the phase 3 noninferiority trial, presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, researchers randomly assigned patients who underwent cytoreductive surgery to letrozole (Femara, Novartis) alone or standard treatment with paclitaxel and carboplatin followed by letrozole.
Results showed letrozole alone did not exhibit noninferiority to the chemotherapy regimen.
“There may be certain considerations if somebody cannot tolerate chemotherapy or doesn’t want chemotherapy that an aromatase inhibitor can be used, but this initial data mandates that the standard of care is carboplatin and paclitaxel followed by an aromatase inhibitor,” Matulonis, chief of the division of gynecologic oncology at Dana-Farber Cancer Institute, told Healio.
For more information:
Ursula A. Matulonis, MD, can be reached at ursula_matulonis@dfci.harvard.edu.
Sources/Disclosures
Source:
Healio Interviews
Reference:
- Fader AN, et al. Results of a randomized phase III trial of letrozole alone versus paclitaxel and carboplatin followed by letrozole as initial treatment for patients with stage II-IV ovarian, fallopian tube, or primary peritoneal low-grade serous carcinoma. Presented at: Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; April 10-13, 2026; San Juan, Puerto Rico.
Disclosures:
Healio could not determine relevant financial disclosures at the time of publication.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply